Reducing Estrogen Dosing in CHC: The Quest to Balance Safety with Tolerability

Reducing Estrogen Dosing in CHC: The Quest to Balance Safety with Tolerability

Reducing Estrogen Dosing in CHC: The Quest to Balance Safety with Tolerability

Reducing the concentration of estrogen in combined oral contraceptives is a delicate balancing act, but how low can you really go?

Available credits: 0.25

Time to complete: 15 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Physicians continue to seek the safest and most effective formulations for combined hormonal contraceptives (CHCs). The goal is to ensure that the patient’s chosen option optimizes the many benefits of estrogen but also reduces its adverse events—particularly those that are cardiovascular and thromboembolic in nature. Lower estrogen concentrations do not always mean better; sometimes better means better. But just like in a game of beach limbo, we have to ask: How low can you go?

    Join us as Dr. Lee Shulman and Barbara Dehn, a nurse practitioner with vast contraception counseling and prescribing experience, discuss the dynamics of a new, lower-strength estrogen with the potential for use in combined oral contraceptives.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Lee P. Shulman, MD, FACMG, FACOG
    The Anna Ross Lapham Professor in Obstetrics and Gynecology
    Feinberg School of Medicine
    Northwestern University
    Chicago, IL 

    Consulting Fees: CooperSurgical
    Commercial Interest Speakers Bureau: Bayer

    Barbara A. Dehn, RN, MS, NP, FAANP, NCMP
    Women’s Health NP
    El Camino Hospital
    Mountain View, CA

    No relevant relationships reported

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Robert S. Schneider, MSW has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the rationale for reducing estrogen content in oral contraceptives
    • Describe the daily quality of life adverse events of current oral contraceptive formulations
    • Summarize data on the potential of estetrol (E4) to reduce safety concerns and daily quality of life adverse events associated with current oral contraceptives 
  • Target Audience

    This activity is designed to meet the educational needs of obstetricians/gynecologists, nurse practitioners, physician assistants, nurses, certified nurse midwives, and primary care physicians with a focus on women’s health.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Mayne Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free